NCT05989711 · Liver disease · Reviewed report linked
Registered study title: IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) Registry source ↗. Registry observation retrieved 2026-09-20; study context checked 2026-09-20.
Registered question: Two histology outcomes at week 24: disease resolution without worsening fibrosis, and fibrosis improvement without worsening disease; the registry also lists adverse events through week 52.
Reviewed report on this study: PMID 41237796: The study met the endpoint of MASH resolution without worsening fibrosis, but did not meet the fibrosis-improvement endpoint without worsening MASH. Adverse events were reported in 78% and 81% of active groups versus 67% with placebo.↗ This abstract-and-record-metadata summary was reviewed 2026-09-15. Read the preserved review version →
Open the exact study context →